

JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office: T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA) Fax: 0091-11-26498341,26494708, Phone: 0091-11-26494519-24

E-mail: admin@jagsonpal.com

CIN: L74899DL1978PLC009181

JPL/Stock-Corr-2013	May 30th, 2018
The Manager Listing Agreement The National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051	The Manager Listing Agreement The Bombay Stock Exchange Ltd. Pherojbhoy Jeejeebhoy Tower Dalal Street, Mumbai - 400 001.
CM Quote : JAGSNPHARM	Scrip Code : 507789

Sir,

- In accordance with SEBI (Listing Obligations And Disclosure Requirements)
 Regulation 2015, please note that the Board of Directors of the Company at its
 meeting held on 30th May, 2018, has approved the Audited Financial Results for
 the year ended 31/03/2018, a copy of which is enclosed for your reference and
 records.
- Approval of Quarterly performance and three months ended 31.03.2018 was approved by the Board of Directors and resolution in this regard was passed with an authority to Managing Director to publish in newspapers and send same to National Stock Exchange of India Limited (NSE) & Bombay Stock Exchange Limited (BSE).
- Auditors Report is enclosed, which is CLEAN, does not contain and any QUALIFICATION.
- The Board recommended dividend @ 2% on Equity Share of Rs. 5/- each paid-up i. e. Rs. 0.10/- per share.
- Other routine matters were discussed by the Board and taken care.
- Any another matter with the permission. Meeting concluded with vote of thanks,
- The meeting commenced at 12.00 noon and concluded at 5.00 p.m.

Thanking you,

Yours faithfully,

For JAGSONPAL PHARMACEUTICALS LIMITED

R K KAPOOR

COMPLIANCE OFFICER & COMPANY SECRETARY

New Delh